J Gastroenterol Hepatol. 2007;22(10):1605-1608. A final diagnosis was established in 22 patients in the mosapride group (73.3%) compared with 15 patients in the control group (50%, P = 0.110 ...

No serious side effects or abnormal laboratory findings were observed for either mosapride or teprenone. Therefore, we believe that the 5-HT 4 agonist, mosapride, can be a first-line drug to treat FD.